Author: FX

AUD/NZD is expected to extend recovery above 1.0950 despite firmer NZ Trade Balance data. A higher NZ labor cost index will escalate inflation projections further. Weaker Australian monthly Retail Sales might ease some troubles for the RBA. The AUD/NZD pair has displayed a sharp recovery move after a gap down open to near 1.0926 in the early Asian session. The cross is picking strength despite the release of the upbeat New Zealand Trade Balance data. Exports in December month improved to $6.72B versus the former release of $6.34B while Imports trimmed to $7.19B from the prior release of $8.52B. The…

(Reuters) -A missile hit an apartment building on Sunday in Kharkiv, Ukraine’s second city, killing one person and injuring others, regional governor Oleh Synehubov said. A Reuters picture from the scene showed fire engulfing part of a residential building. Synehubov said the strike took place in the city’s central Kyiv district. “According to updated information, one person has died as a result of a strike by a Russian missile on a residential building,” Synehubov wrote on Telegram. There was no immediate indication of how many people were injured. Synehubov, who earlier put the number of injured at three, said casualties…

Alexandria Real Estate Equities Q4 Earnings Preview Source link

Potlatch Q4 2022 Earnings Preview Source link

NXP Semiconductors Q4 2022 Earnings Preview Source link

Via eFX:Barclays Research provides the output of its month-end fixing model.”The passive rebalancing model at month-end points to strong USD selling against all majors except for EUR and JPY, where the signal is moderate,” Barclays notes.”We now publish our month-end signal earlier. Our analysis shows that trading earlier (a few days before month-end) improves the model’s performance. Strategies with longer holding periods perform better than our default strategy, which looks at FX performance from noon to 4PM GMT the day of month-end and has shown declining returns over the past few years. This suggests that flows are now spread over…

© Reuters. Israeli Border police officers stand at the house of Palestinian gunman Khaire Alkam in A-Tur in East Jerusalem, after Alkam shot dead at least seven people near a synagogue in Neve Yaacov which lies on occupied land that Israel annexed to Jerusalem after JERUSALEM (Reuters) -Israeli police sealed off the Jerusalem family home of a Palestinian gunman on Sunday, two days after he killed seven people outside a synagogue, as fears grew of escalation in the deadliest unrest for years in Jerusalem and the West Bank. Prime Minister Benjamin Netanyahu announced plans to make it easier for Israelis…

jacoblund/iStock via Getty Images December’s credit card metrics extended their long, gradual path to prepandemic level of delinquencies and net charge-offs, as seen in the table below. With pandemic-era fiscal relief programs largely over, more consumers have been falling behind on credit card payments. At most credit card companies, both metrics worsened from November, but remain better than December 2019 levels. The notable exceptions are JPMorgan Chase (NYSE:JPM), which saw its net charge-off rate of 1.24% drop from 1.64%, and Synchrony Financial (NYSE:SYF), which saw its adjusted net charge-off rate slide to 3.4% from 3.7%. One company, though, experienced a…

Sam Bankman-Fried’s legal team is seeking to remove a bail condition that prevented him from accessing FTX funds, according to court filings from Jan. 28. A letter from Bankman-Fried’s lawyer, Mark Cohen, to United States District Court Judge Lewis Kaplan stated that Bankman-Fried should have access to assets held by FTX, claiming the client was not involved in previous unauthorized transactions.Continue Reading on Coin Telegraph Source link

vzphotos After generating $208B in sales over two decades, AbbVie’s (NYSE:ABBV) monopoly over its world’s bestselling therapy Humira (adalimumab) is about to end this week as copycat versions enter the U.S. market. A self-administered injectable indicated for rheumatoid arthritis and other autoimmune conditions, Humira brought $21B worldwide sales for AbbVie (ABBV) in 2021, accounting for more than a third of its topline and becoming the world’s top-selling drug for the tenth consecutive year. Thanks to patent extension strategies and legal settlements, the company has maintained its blockbuster status since former parent Abbott Laboratories (ABT) won the first U.S. approval for…